# EDGAR Filing Document

**Accession Number:** 0001764013
**File Stem:** 0001764013-25-000104
**Filing Date:** 2025-7
**Character Count:** 2441
**Document Hash:** 8a923d32400bebcc1143b4530e34cdaa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001764013-25-000104.hdr.sgml**: 20250709

**ACCESSION NUMBER**: 0001764013-25-000104

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250709

**DATE AS OF CHANGE**: 20250709

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunovant, Inc.
- **CENTRAL INDEX KEY:** 0001764013
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832771572
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38906
- **FILM NUMBER:** 251114109

**BUSINESS ADDRESS:**
- **STREET 1:** 320 WEST 37TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 917-580-3099

**MAIL ADDRESS:**
- **STREET 1:** 320 WEST 37TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Health Sciences Acquisitions Corp
- **DATE OF NAME CHANGE:** 20190108

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

**(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;)**

Filed by the Registrant ☒&nbsp;&nbsp;&nbsp;&nbsp;

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy Statement

☐&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ &nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement

☒ &nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material Pursuant to § 240.14a-12

**IMMUNOVANT, INC.**

**(Name of Registrant as Specified In Its Charter)**

Payment of Filing Fee (Check all boxes that apply):

☒ &nbsp;&nbsp;&nbsp;&nbsp;No fee required.

☐ &nbsp;&nbsp;&nbsp;&nbsp;Fee paid previously with preliminary materials.

☐ &nbsp;&nbsp;&nbsp;&nbsp;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    

------

![immunovantinc_vxnaxp35765x.jpg](immunovantinc_vxnaxp35765x.jpg)

------

![immunovantinc_vxnaxp35765xa.jpg](immunovantinc_vxnaxp35765xa.jpg)

<br>